SCAI Comments on Proposed Medicare Coverage Policies Restricting Invasive FFR Procedures
November 19, 2020—The Society for Cardiovascular Angiography and Interventions (SCAI) announced that it continues to oppose proposed local Medicare coverage policies that would restrict patient access to invasive fractional flow reserve (FFR) tests.
PIONEER III Findings Presented for Sinomed’s Supreme HT DES
November 17, 2020—Sino Medical Sciences Technology Inc. (Sinomed), a Tianjin, China–based developer of neuro- and cardiovascular technologies, announced data from the randomized, global PIONEER III study evaluating the safety and efficacy of the Supreme HT healing-targeted drug-eluting stent (DES).
Korean Study Supports Safety and Feasibility of 1-Month DAPT After Stent Placement
November 15, 2020—A 1-month treatment of dual antiplatelet therapy (DAPT) is safe and as effective as a longer duration of therapy at preventing cardiac events in patients 1 year after stent placement, according to a study led by Myeong-Ki Hong, MD, professor of cardiology at Yonsei University College of Medicine, Severance Cardiovascular Hospital in Seoul, Korea.
ALPHEUS Trial Finds Ticagrelor Is Not Superior to Clopidogrel to Reduce MI Risk During PCI
November 14, 2020—The use of ticagrelor was found to be not superior to clopidogrel in the reduction of the rate of heart attack or severe complications among patients undergoing elective percutaneous coronary intervention (PCI) in the randomized, international, multicenter ALPHEUS trial.
First Patients Treated in Feasibility Study of Abiomed’s 9-F Impella ECP Expandable Percutaneous Heart Pump
October 28, 2020—Abiomed announced that the first two patients have been treated with the Impella ECP expandable percutaneous heart pump, which is being studied in an FDA early feasibility study.
COBRA-REDUCE Evaluates Shorter Duration DAPT After PCI With Nano-Coated Coronary Stent
October 17, 2020—The results of the COBRA-REDUCE trial demonstrated that for patients undergoing percutaneous coronary intervention (PCI) who also require oral anticoagulation, treatment with a nanotechnology polymer-coated stent plus 14-day dual antiplatelet therapy (DAPT) did not reduce bleeding or establish noninferior outcomes for thrombotic events compared with a drug-eluting stent (DES) and standard 3- or 6-month DAPT therapy.
DES With Durable Polymers Are Noninferior to Biodegradable DES in HOST-REDUCE-POLYTECH-ACS Trial
October 17, 2020—An investigator-initiated randomized clinical trial (RCT) found that drug-eluting stents (DES) with durable polymers are noninferior to DES with biodegradable polymers in patients with acute coronary syndrome (ACS).
Findings Reported From DEFINE-FLOW Study of Deferral of PCI in FFR-Abnormal Lesions With Preserved Coronary Flow Reserve
October 16, 2020—A new observational study of deferred lesions following combined fractional flow reserve (FFR) and coronary flow reserve (CFR) assessments found that untreated vessels with abnormal FFR but intact CFR do not have noninferior outcomes compared to those with an FFR > 0.8 and a CFR ≥ 2.0 when treated medically.
Physiology-guided PCI Optimization Strategy Evaluated in TARGET FFR Study
October 16, 2020—Results from the randomized controlled TARGET FFR trial showed that while a physiology-guided percutaneous coronary intervention (PCI) optimization strategy did not achieve a significant increase in the proportion of patients with final FFR ≥ 0.9, it reduced the proportion of patients with a residual FFR ≤ 0.8 after PCI.
FORECAST Trial Investigates Cost and Clinical Advantage of FFR Derived From CT
October 16, 2020 –The use of fractional flow reserve management derived from computed tomography (FFRCT) did not significantly reduce costs but did reduce the use of invasive coronary angiography (ICA) in the FORECAST randomized clinical trial.
Interim Analysis Presented From PROTECT III Study of Abiomed’s Impella Device in High-Risk PCI Patients
October 15, 2020—Abiomed announced that new data from an interim analysis of the PROTECT III study demonstrate reduced rates of major adverse cardiac and cerebrovascular events (MACCEs; a composite of death, stroke, myocardial infarction, and repeat procedures) when the company’s Impella device is used to achieve more complete revascularization in a single setting for high-risk percutaneous coronary intervention (PCI) patients.
Shorter DAPT Regimen With Abbott's Xience V DES Is Noninferior to Standard DAPT for Ischemic Events
October 15, 2020—Results from the XIENCE 90/28 clinical trials presented by Roxana Mehran, MD, at TCT Connect have shown that a shorter course of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) was noninferior to standard DAPT up to 12 months.
1-Year DEFINE PCI Data Presented for Philips' iFR-Guided Interventions
October 15, 2020—Royal Philips announced that the 1-year results of the DEFINE PCI study were presented at TCT Connect, the 32nd annual Transcatheter Cardiovascular Therapeutics scientific symposium of the Cardiovascular Research Foundation held online October 14-18, 2020.
Abiomed’s Restore EF Study Demonstrates Impella-Supported High-Risk PCI Improves LVEF
October 14, 2020—Abiomed announced that findings from the Restore EF study demonstrated that the use of contemporary best practices—including attempting a more complete revascularization with the company’s Impella-supported high-risk percutaneous coronary intervention (PCI)—is associated with significant improvement of left ventricular ejection fraction (LVEF), heart failure symptoms, and anginal symptoms at follow-up.
Compensation in the Cardiovascular Practice in 2020
Recent MedAxiom reports offer insights on compensation trends for cardiovascular providers and advanced practice providers, as well as an early look at how COVID-19 impacted practices.
By Joel Sauer, MBA, and Ginger Biesbrock, PA-C, MPH, MPAS, AACC
US Device Guide
This Device Guides offers a searchable, comprehensive listing of the available interventional cardiology devices in the United States.
European Device Guide
This Device Guides offers a searchable, comprehensive listing of the available interventional cardiology devices in Europe.